Prednisolone and Prednisone in Dogs and Cats: Pharmacology, Dosing, and Adverse Effect Management

Bottom line

• In cats, always prescribe prednisolone, not prednisone. Cats have markedly reduced hepatic 11β-hydroxysteroid dehydrogenase activity, so oral prednisolone achieves roughly 100% bioavailability versus ~21% for prednisone — a ~4-fold difference in plasma exposure. In dogs, prednisone and prednisolone are therapeutically equivalent at equal doses [1][2].
• Dose by intent: anti-inflammatory 0.5–1 mg/kg/day PO (dog and cat); immunosuppressive 2–4 mg/kg/day PO in dogs and 2–3 mg/kg/day PO in cats (often divided BID initially in severe disease), always followed by a structured taper once remission is reached [8].
• Adverse effects are dose-, duration-, and frequency-dependent: PU/PD/PP at anti-inflammatory doses; muscle wasting, steroid hepatopathy, iatrogenic hyperadrenocorticism, and secondary diabetes mellitus at prolonged immunosuppressive doses. Body condition matters — over-conditioned cats reach ~2-fold higher plasma prednisolone than lean cats on the same dose, so dose to lean body weight in obese patients [3].
• Taper slowly: the most common cause of relapse in immune-mediated disease is tapering too fast, and the most common cause of iatrogenic Cushing's is failing to taper at all. Reduce by ≤25% of the current dose every ~3–4 weeks once the target endpoint is stable, moving toward alternate-day therapy at the lowest effective dose [5].
• This is a clinician-facing evidence summary — not a dosing protocol. Confirm regimen, monitoring, and contraindications against current product labeling and a veterinary formulary.

Drug facts

• Class: Synthetic glucocorticoid (intermediate-acting) [8].
• Prodrug vs. active drug: Prednisone is an inactive prodrug converted to active prednisolone by hepatic 11β-hydroxysteroid dehydrogenase (11β-HSD). Dogs (and humans) convert efficiently; cats do not — this is the pharmacokinetic basis for the species-specific recommendation [1][2].
• Mechanism: Binds the cytosolic glucocorticoid receptor → nuclear translocation → transactivation and transrepression of gene targets; suppresses NF-κB and AP-1 signaling; reduces transcription of pro-inflammatory cytokines (IL-1, IL-6, TNF-α); inhibits phospholipase A2 (↓ prostaglandins, leukotrienes); and reduces leukocyte trafficking [8].
• Formulations: Prednisolone tablets (1, 5, 20 mg); prednisolone sodium succinate IV/IM; prednisone tablets (1, 5, 20, 50 mg). Compounded oral liquids are available.
• Anti-inflammatory dose: 0.5–1 mg/kg/day PO (dog and cat) [8].
• Immunosuppressive dose: 2–4 mg/kg/day PO in dogs; 2–3 mg/kg/day PO in cats — divided BID initially in severe disease. For specific immune-mediated cytopenias, disease-specific consensus doses are lower and are covered below [5][8].
• Approval/formulary status: Widely used per veterinary formulary indications across inflammatory and immune-mediated disease; many uses in cats are label-off. Confirm species-specific dosing against Plumb's Veterinary Drug Handbook or equivalent.
• Key contraindications/cautions: systemic fungal infection, uncontrolled infection without concurrent therapy, poorly controlled diabetes mellitus, and concurrent NSAID use (GI ulceration risk). Screen cats for occult HCM before immunosuppressive dosing (sodium/water retention can decompensate CHF).

Does prednisolone vs. prednisone actually matter? (species pharmacokinetics)

Cats — yes, decisively. The clinical importance was established by Graham-Mize & Rosser (2004), who documented that oral prednisolone bioavailability in cats is approximately 100% versus approximately 21% for prednisone at the same mg/kg dose, attributed to reduced first-pass hepatic conversion [1]. This was independently corroborated by a verified feline study (Lowe et al. 2008, Vet Rec), which reported significantly higher plasma prednisolone concentrations after oral prednisolone than after an equivalent oral prednisone dose — consistent with the ~4-fold exposure gap [2].

The practical consequence: a cat that appears "resistant" to an adequate prednisone dose is usually failing on pharmacokinetic grounds, not pharmacodynamic ones. Switching to prednisolone at the same mg/kg dose typically restores response. Erratic prednisone→prednisolone conversion also makes therapeutic monitoring unreliable in cats.

Dogs — no clinically significant difference. At standard oral doses there is no meaningful pharmacokinetic gap between the two formulations; selection is driven by formulation availability, cost, and client preference.

What drives adverse effects, and how do dogs and cats differ? (safety / AEs)

The adverse-effect profile is directly proportional to dose, duration, and frequency of administration.

Dogs

• PU/PD/PP: virtually universal at immunosuppressive doses; onset within 24–48 hours.
• Steroid hepatopathy: ALT/ALP elevation common; vacuolar hepatopathy on biopsy; reversible with dose reduction.
• Muscle wasting (gluconeogenesis from protein catabolism): significant beyond ~4 weeks at immunosuppressive doses.
• Iatrogenic hyperadrenocorticism: truncal alopecia, pot-belly, calcinosis cutis — typically after months of sustained dosing.
• Diabetes mellitus: risk rises with cumulative dose, especially in predisposed breeds (Samoyeds, Keeshonds).
• GI ulceration: markedly increased when combined with NSAIDs; use GI protectants (omeprazole, sucralfate) in high-risk patients.

Cats

• More resistant than dogs to steroid hepatopathy and steroid-induced diabetes at anti-inflammatory doses, but notably susceptible at prolonged immunosuppressive doses. Diabetogenic risk is clinically significant at >2 mg/kg/day sustained beyond ~4 weeks.
• More susceptible to infectious complications (Toxoplasma reactivation, systemic fungal disease) at immunosuppressive doses.
• CHF exacerbation is possible from sodium/water retention — screen for underlying HCM before starting immunosuppressive therapy.

Body condition is an under-recognized modifier in cats. A verified 2013 pharmacokinetic study (Center SA et al., Res Vet Sci) found that over-conditioned cats achieved approximately 2-fold higher plasma prednisolone concentrations than normal-conditioned cats after a single oral prednisolone dose, which the authors proposed may explain the perceived increased risk of glucocorticoid-associated side effects in obese cats [3]. Because obese cats are already predisposed to iatrogenic diabetes, higher drug exposure compounds the risk — the consensus mitigation is to dose to lean body weight, not actual body weight.

Special populations: iatrogenic diabetes in cats (2025 iCatCare guidance)

As of November 2025, the iCatCare consensus guidelines on the diagnosis and management of diabetes mellitus in cats (Taylor S et al., J Feline Med Surg) provide the most current framework and are directly relevant to glucocorticoid stewardship [4]:

• Glucocorticoids are named a major cause of secondary feline diabetes mellitus, particularly with immunosuppressive courses (≥2 mg/kg/day for >3–4 weeks).
• The guidelines recommend proactive glycemic monitoring (fructosamine or home glucose monitoring) during any prolonged glucocorticoid course in at-risk cats.
• Highest-risk cats: obese cats, male cats, and cats with concurrent hypersomatotropism.
• Early identification and dose reduction can allow remission of glucocorticoid-induced diabetes if insulin resistance is reversed.

Together with the body-condition PK data above, the actionable message is: in any cat on prednisolone ≥1 mg/kg/day beyond ~3 weeks, track body weight, BCS, and glycemia, and dose obese cats to lean body weight.

Efficacy in immune-mediated disease: canine IMHA and the ACVIM framework

Canine immune-mediated hemolytic anemia (IMHA) is a life-threatening destruction of red blood cells. Primary (idiopathic) disease accounts for ~60–75% of cases; secondary IMHA arises with infectious agents, neoplasia, or drugs. Untreated mortality exceeds 50%; with appropriate immunosuppression, 30-day survival is ~70–80% [7].

The 2019 ACVIM Consensus Statement on the Treatment of Immune-Mediated Hemolytic Anemia in Dogs (Swann JW et al., J Vet Intern Med) is the standard-of-care framework [5]:

Initial dosing

• Prednisolone 1–2 mg/kg/day PO (or IV methylprednisolone sodium succinate 1 mg/kg in severely ill, non-oral patients).
• Reserve the higher immunosuppressive end (2 mg/kg/day) for severe, rapidly progressive, or transfusion-dependent cases.
• In dogs >25 kg, body-surface-area dosing (50–60 mg/m²/day) may reduce adverse effects.

When to taper

• Do not begin tapering until PCV is stable at ≥30% for at least 3 consecutive days.
• Taper by ≤25% of the current dose every 3–4 weeks.
• Total treatment duration is typically 4–6 months; some dogs require longer.
• Monitor CBC q2–4 weeks during taper; halt the taper if PCV falls below 30%.

What to monitor: PCV/HCT and reticulocytes (q24–48h while hospitalized, q2–4 weeks outpatient); BUN, creatinine, and urine output (screen for concurrent renal ischemia); and urine sediment/culture (immunosuppressed dogs are predisposed to UTI).

Comparators and add-ons: where secondary immunosuppressants fit (multimodal)

Long-term immunosuppressive prednisolone in dogs causes substantial quality-of-life impairment (PU/PD, weight gain, muscle wasting). Adding a steroid-sparing agent after induction allows faster tapering to lower prednisolone doses. The 2024 ACVIM Consensus Statement on the Treatment of Immune Thrombocytopenia in Dogs and Cats (LeVine DN et al., J Vet Intern Med) — the most recent ACVIM statement on immune-mediated cytopenia — reinforces that glucocorticoids remain first-line across immune-mediated cytopenias, with mycophenolate mofetil and cyclosporine as evidence-based second-line options [6].

Where the evidence is contested — and the neutral synthesis. Both ACVIM statements agree glucocorticoids are first-line, but they diverge on how confident we can be about second-line sequencing. The 2019 IMHA statement offers relatively specific guidance on adding secondary agents in severe or refractory disease [5], whereas the 2024 ITP statement, built on a structured PICO/Delphi review of 288 articles, explicitly emphasizes the low evidence quality for which secondary agent to choose, when, and at what dose — concluding that these remain open questions [6]. The reconciled clinical position: initiate with glucocorticoid monotherapy in most cases, and reserve secondary immunosuppressants for refractory or very severe presentations rather than adding them routinely at induction. Both statements support that stance.

Agent	Species	Role / evidence basis	Onset
Azathioprine	Dog only (contraindicated in cats — very low TPMT activity → fatal myelosuppression)	Second-line add-on for refractory IMHA/IMPA/IBD; retrospective data, no RCT	4–6 weeks
Mycophenolate mofetil (MMF)	Dog and cat	Second-line; less myelosuppression than azathioprine; included in ACVIM 2024 ITP consensus options	2–4 weeks
Cyclosporine / ciclosporin	Dog and cat	Second-line; rapid onset (~3–5 days); also atopic dermatitis, IBD, IMPA	4–6 weeks (immunosuppression); ~3–5 days onset
Chlorambucil	Cat preferred	Preferred purine-analog alternative in cats; lymphoplasmacytic IBD, low-grade lymphoma	4–8 weeks
Human IVIg (hIVIg)	Dog and cat	Severe/rapidly progressive cases with imminent transfusion failure; 0.5–1.5 g/kg IV	Acute

Critical caveat repeated because it is fatal to miss: azathioprine is contraindicated in cats. Thiopurine methyltransferase activity is very low in cats, causing fatal bone marrow suppression even at low doses. Chlorambucil is the preferred steroid-sparing purine analog in cats.

Contraindications, precautions & PK

• Contraindications / strong cautions: systemic fungal infection; uncontrolled bacterial infection without concurrent antimicrobial cover; poorly controlled diabetes mellitus; concurrent NSAID administration (GI ulceration).
• Cats specifically: screen for occult HCM before immunosuppressive dosing (sodium/water retention risk); anticipate elevated diabetogenic and infectious-complication risk at ≥2 mg/kg/day beyond ~4 weeks; dose obese cats to lean body weight given ~2-fold higher plasma exposure [3][4].
• HPA-axis PK: HPA suppression occurs within ~2 weeks of immunosuppressive dosing and recovers gradually (weeks to months) after cessation. Abrupt withdrawal after >3–4 weeks of therapy risks an Addisonian-like withdrawal syndrome (lethargy, hypotension, vomiting) — hence the mandatory taper [5].
• Prodrug PK: because prednisone relies on hepatic conversion, hepatic insufficiency and (in cats) constitutively low 11β-HSD activity both reduce active-drug exposure; prednisolone bypasses this and is the reliable choice whenever conversion is in doubt [1][2].

Practical decision support

Baseline before starting (any prolonged course): CBC, chemistry (ALT, ALP, BUN, creatinine, glucose), urinalysis, and urine culture — especially in cats, where glucocorticoid-induced dilute urine plus immunosuppression raises UTI risk. In cats, add body weight, BCS, and fructosamine.

Recheck cadence: at 2–4 weeks (response assessment, glucose, liver enzymes, CBC for lymphopenia); then every 4–8 weeks during tapering; then every 6 months during maintenance. For immune-mediated cytopenias, follow the disease-specific monitoring above (e.g., PCV/reticulocytes in IMHA).

Guideline-based canine IMHA taper (illustrative):

Phase	Action
Weeks 0–4	Prednisolone 2 mg/kg/day if severe; 1 mg/kg/day if moderate
PCV ≥30% × 3 days	Begin taper
Each 3–4 week interval	Reduce by ≤25% of the current dose
~Month 4–6	Discontinue if in remission (PCV ≥35%, no spherocytes)

Cat-specific dosing snapshot (prednisolone):

Indication	Typical prednisolone dose	Notes
Anti-inflammatory	0.5–1 mg/kg/day PO	Taper over 4–8 weeks; dose to lean BW in obese cats
Immunosuppressive (IMHA, immune dermatoses)	1–2 mg/kg/day PO (up to 2–3 in severe disease)	Monitor PCV, glucose, fructosamine
Adjuvant (lymphoma, IBD)	1–2 mg/kg/day PO	Titrate to response; chlorambucil preferred as feline steroid-sparing agent

Three habits that reduce morbidity: use the lowest effective dose; transition to alternate-day therapy as early as remission allows; and add a steroid-sparing agent in any case requiring >6–8 weeks of immunosuppressive dosing. Always confirm specific doses, monitoring schedules, and contraindications against current product labeling, Plumb's Veterinary Drug Handbook, or an equivalent formulary.

Frequently Asked Questions

Why is prednisolone preferred over prednisone in cats? Cats have markedly reduced hepatic 11β-hydroxysteroid dehydrogenase activity and convert the prednisone prodrug to active prednisolone poorly. Oral prednisolone bioavailability is ~100% versus ~21% for prednisone — roughly a 4-fold difference in plasma exposure — so prednisolone gives reliable, predictable dosing [1][2].

Are prednisone and prednisolone interchangeable in dogs? Effectively yes. At standard oral doses dogs convert prednisone to prednisolone efficiently, with no clinically significant pharmacokinetic difference; choose based on availability, cost, and client preference [1].

What are the anti-inflammatory versus immunosuppressive doses? Anti-inflammatory: 0.5–1 mg/kg/day PO in dogs and cats. Immunosuppressive: 2–4 mg/kg/day PO in dogs and 2–3 mg/kg/day PO in cats, often divided BID initially. Disease-specific consensus doses (e.g., IMHA 1–2 mg/kg/day) may be lower [5][8].

How should prednisolone be tapered in immune-mediated disease? Begin only after the target endpoint is stable (for canine IMHA, PCV ≥30% for ≥3 consecutive days), then reduce by ≤25% of the current dose every 3–4 weeks toward alternate-day therapy at the lowest effective dose. Tapering too fast is the leading cause of relapse [5].

Should obese cats be dosed differently? Yes. Over-conditioned cats reach ~2-fold higher plasma prednisolone than lean cats on the same dose, compounding an already-elevated diabetes risk. Dose to lean body weight and monitor glycemia [3][4].

Which steroid-sparing agent should I avoid in cats? Azathioprine. Feline thiopurine methyltransferase activity is very low, and azathioprine can cause fatal bone-marrow suppression even at low doses. Use chlorambucil as the preferred purine-analog alternative in cats [5][6].

Does prednisolone cause diabetes in cats, and is it reversible? Glucocorticoids are a major cause of secondary feline diabetes, especially at ≥2 mg/kg/day for >3–4 weeks. Per the 2025 iCatCare guidelines, early recognition and dose reduction can allow remission if insulin resistance is reversed — so monitor fructosamine/home glucose during prolonged courses [4].

When should I add a second immunosuppressant rather than escalate prednisolone? Both the 2019 ACVIM IMHA and 2024 ACVIM ITP statements support glucocorticoid monotherapy first, reserving secondary agents (MMF, cyclosporine; azathioprine in dogs only) for refractory or very severe disease. The 2024 statement stresses the low evidence quality for specific agent selection, so individualize and monitor closely [5][6].

Changelog

• 2026-07-06: Consolidated into a single evergreen hub. Merged two dated dispatch spokes (feline prednisolone/prednisone bioavailability + 2025 iCatCare diabetes guidance; ACVIM 2019 IMHA prednisolone taper protocol + 2024 ACVIM ITP context) into the hub spine. Deduplicated the shared feline-bioavailability material; folded in body-condition PK and iCatCare 2025 diabetes evidence and the IMHA/ITP taper and steroid-sparing framework. During citation integrity review, corrected several identifiers carried by the source posts: Lowe 2008 Vet Rec PMID → 18552328 (10.1136/vr.162.24.777); the 2013 feline body-condition PK study reattributed to its verified authorship (Center SA et al., Res Vet Sci 2013;95(1):225–230, PMID 23473553); Piek IMHA study corrected to J Vet Intern Med 2008;22(2):366–373 (PMID 18346140); ACVIM IMHA consensus dated to 2019 (Swann et al., 10.1111/jvim.15463). The Graham-Mize & Rosser 2004 bioavailability abstract is a genuine, widely-cited Vet Dermatol supplement reference but its content could not be independently re-verified against a resolving open URL, so it is flagged for editorial confirmation; its core finding is independently corroborated by the verified Lowe 2008 study.
• 2026-06-29: Source posts first published.